45,991 Shares in Encompass Health Corporation $EHC Purchased by AlphaCore Capital LLC

AlphaCore Capital LLC purchased a new position in Encompass Health Corporation (NYSE:EHC) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 45,991 shares of the company’s stock, valued at approximately $4,881,000.

Several other institutional investors have also modified their holdings of EHC. Thrivent Financial for Lutherans boosted its stake in Encompass Health by 57.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 1,194,859 shares of the company’s stock valued at $151,544,000 after purchasing an additional 437,464 shares in the last quarter. Jennison Associates LLC boosted its stake in Encompass Health by 12.8% during the 3rd quarter. Jennison Associates LLC now owns 894,511 shares of the company’s stock valued at $113,621,000 after purchasing an additional 101,274 shares in the last quarter. Tudor Investment Corp ET AL boosted its stake in Encompass Health by 155.3% during the 3rd quarter. Tudor Investment Corp ET AL now owns 210,712 shares of the company’s stock valued at $26,765,000 after purchasing an additional 128,191 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Encompass Health by 5.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,410,335 shares of the company’s stock valued at $179,141,000 after purchasing an additional 70,387 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in Encompass Health by 170.9% during the 3rd quarter. AlphaQuest LLC now owns 29,916 shares of the company’s stock valued at $3,800,000 after purchasing an additional 18,874 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Price Performance

EHC opened at $106.64 on Friday. The stock has a fifty day moving average of $102.94 and a 200-day moving average of $106.40. The firm has a market capitalization of $10.58 billion, a P/E ratio of 17.80, a PEG ratio of 2.32 and a beta of 0.72. Encompass Health Corporation has a 12-month low of $92.77 and a 12-month high of $127.99. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last released its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.51 by $0.09. The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.28% and a net margin of 10.04%.The company’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities analysts forecast that Encompass Health Corporation will post 5.96 EPS for the current fiscal year.

Encompass Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Wednesday, July 1st will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is currently 12.69%.

Analyst Upgrades and Downgrades

EHC has been the subject of a number of research reports. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Barclays decreased their price target on Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $144.17.

Insider Buying and Selling at Encompass Health

In related news, Treasurer Edmund Fay sold 11,937 shares of the stock in a transaction on Monday, March 9th. The stock was sold at an average price of $107.00, for a total transaction of $1,277,259.00. Following the completion of the sale, the treasurer directly owned 89,325 shares in the company, valued at approximately $9,557,775. This trade represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Patrick William Tuer sold 682 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the sale, the executive vice president owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.80% of the stock is currently owned by company insiders.

Key Headlines Impacting Encompass Health

Here are the key news stories impacting Encompass Health this week:

• Positive Sentiment: Zacks Research raised its FY2027 EPS estimate to $6.35 from $6.32, suggesting stronger profit growth over the next couple of years.
• Positive Sentiment: The firm also increased its FY2028 EPS forecast to $7.16 from $7.13 and lifted Q1 2028 EPS to $1.80 from $1.73, reinforcing a favorable longer-term earnings trend.
• Positive Sentiment: Despite the revisions, the latest consensus still points to solid earnings for Encompass Health, with analysts expecting about $5.97 per share for the current full year and a “Buy” consensus recommendation from analysts. Article: Encompass Health Corporation (NYSE:EHC) Receives Consensus Recommendation of “Buy” from Analysts
• Neutral Sentiment: Several shorter-term estimates were only slightly adjusted, including FY2026 EPS cut to $5.96 from $6.03, with Q2 2026 lowered to $1.46 from $1.49 and Q3 2026 lowered to $1.36 from $1.40.
• Neutral Sentiment: Other quarterly forecasts were modestly lowered as well, including Q2 2027 to $1.60 from $1.62, Q3 2027 to $1.48 from $1.49, and Q4 2027 to $1.64 from $1.65.

About Encompass Health

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.